ERAS
What one share of Erasca holds
Pharmaceutical Preparations
We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer globally each year.
Erasca’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.97 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.33 |
| Dividends | $0.00 |
| Cash and investments | $1.23 |
| Book value | $1.16 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$4.83 | $0.04 | −$1.60 | — | −$5.20 |
| 2021 | — | −$1.85 | $0.17 | −$1.37 | — | $3.83 |
| 2022 | — | −$1.99 | $0.12 | −$0.97 | $0.00 | $2.76 |
| 2023 | — | −$0.83 | $0.01 | −$0.69 | $0.00 | $2.10 |
| 2024 | — | −$0.69 | $0.00 | −$0.47 | $0.00 | $1.50 |
| 2025 | — | −$0.44 | $0.00 | −$0.34 | $0.00 | $1.14 |